作者: Stephen M. Ansell , Lucy S. Hodge , Suzanne R. Hayman
DOI: 10.1007/978-1-4614-8520-9_24
关键词:
摘要: Waldenstrom’s macroglobulinemia is an indolent B-cell malignancy defined by a lymphoplasmacytic infiltration in the bone marrow or other organs including lymph nodes, liver, and spleen, as well monoclonal immunoglobulin M protein (IgM) serum. The of extramedullary sites malignant B lymphocytes, elevated IgM levels, typically leads to symptoms associated with this disease. While follows course, disease remains incurable current therapy. Due heterogeneous clinical presentation, presence multiple comorbidities competing causes death, decision treat patients choice treatment can be complex many do not require initially. When therapy, it important select therapies that limit future options. To provide simple risk-adapted approach managing macroglobulinemia, rational presented.